This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)?
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: To determine if the effect of sertraline in the depression in Alzheimer’s disease study – 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.; Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression […]
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease
Burns, Alistair,
Perry, Elaine,
Holmes, Clive,
Francis, Paul,
Morris, Julie,
Howes, Melanie-Jayne R.,
Chazot, Paul,
Lees, George,
Ballard, Clive
Background/aims: Behavioural and psychological symptoms (BPSD) are frequent in people with Alzheimer’s disease and cause considerable stress to patients and their carers. Antipsychotics have been widely used as a first-line treatment, resulting in an estimated 1,800 excess strokes and 1,600 excess deaths in the UK alone. Safe and effective alternatives are urgently needed. Based upon […]
A pilot usability study of MINWii, a music therapy game for demented patients
MINWii is a music therapy game for the renarcissization of demented patients. It lets players improvise or play songs of their choice by pointing at a virtual keyboard with a Wiimote Pistol. We present the results of a three-month usability study we conducted with 7 institutionalized patients suffering from mild to moderately severe Alzheimer’s disease […]
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
Ashford, J. W.,
Adamson, M.,
Beale, T.,
La, D.,
Hernandez, B.,
Noda, A.,
Rosen, A.,
O'Hara, R.,
Fairchild, J. K.,
Spielman, D.,
Yesavage, J. A.
Objectives: Magnetic Resonance Spectroscopy (MRS) may provide a precise and reliable assessment of the extent and severity of neural tissue loss caused by various diseases. In particular, the N-Acetyl Aspartate (NAA) and Creatine (Cr) ratio has been found to be an indicator of the degree of neuronal loss in Alzheimer’s disease (AD). Memantine is thought […]
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease
Articus, K.,
Baier, M.,
Tracik, F.,
Kühn, F.,
Preuss, U. W.,
Kurz, A.
Background: Cholinesterase inhibitors form the mainstay of treatment for persons with mild-to-moderate Alzheimer’s disease (AD). The rivastigmine patch may increase compliance and the proportion of patients maintaining an efficacious dose compared with oral cholinesterase inhibitors.; Objective: To investigate the proportion of patients who reached and maintained the target rivastigmine patch dose compared with the target […]
Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil
Alvarez, X. Anton,
Cacabelos, R.,
Sampedro, C.,
Couceiro, V.,
Aleixandre, M.,
Vargas, M.,
Linares, C.,
Granizo, E.,
García-Fantini, M.,
Baurecht, W.,
Doppler, E.,
Moessler, H.
Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer’s disease (AD). We compared the safety and efficacy of the neurotrophic compound Cerebrolysin (10 ml; n=64), donepezil (10 mg; n=66) and a combination of both treatments (n=67) in mild-to-moderate (mini-mental state examination-MMSE score 12-25) probable AD patients enrolled in […]
Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14-20) included in a dose-finding study (ITT data set: N = 51; MMSE: 14-25). Results of the […]
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses
Objective: In Alzheimer’s disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items.; Methods: This exploratory analysis focused on the Alzheimer’s Disease Cooperative Study Activities of Daily Living […]
Spine Surgery under general anesthesia may not increase the risk of Alzheimer’s disease
Background: Volatile anesthetics cause Alzheimer’s disease (AD)-like neuropathology in animals. We determined whether spine surgery under general anesthesia and anesthetic choice contributed to AD development.; Methods: We searched the Clinical Data Repository of the University of Virginia for patients receiving spine surgery from January 1, 1992 to March 1, 2004. Patients with newly-diagnosed AD after […]